Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2026-03-11 @ 9:09 PM
Study NCT ID:
NCT00987766
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2009-09-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
VICC GI 0906
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |